Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs
Authors:
- Andras G LackoALAndras G Lacko
- Maya NairMNMaya Nair
- Laszlo ProkaiLaszlo Prokai
- Walter J McConathyWMWalter J McConathy
- 31 October 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 4 (6) , 665-675
Abstract
This review evaluates drug delivery systems that involve intact plasma lipoproteins or some of their components. These complex macromolecules transport highly water-insoluble compounds (cholesteryl esters and triacylglycerols) in their natural environment – a property that renders them ideal carriers of hydrophobic drugs. Particular emphasis is placed on the application of lipoproteins as drug delivery agents in cancer chemotherapy. The history and present activity regarding lipoprotein-based formulations are reviewed, with the primary focus on the smaller sized (low and high density) lipoprotein-based formulations and their potential clinical and commercial value. The use of both native and synthetic lipoproteins as drug delivery agents are discussed from the standpoint of therapeutic efficacy, as well as commercial feasibility. The advantages of lipoprotein-based drug delivery formulations are compared with other drug delivery models, with the primary focus on liposomal preparations. Finally, an expert ...Keywords
This publication has 95 references indexed in Scilit:
- Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiformeInternational Journal of Pharmaceutics, 2007
- Emerging drugs to replace current leaders in first-line therapy for breast cancerExpert Opinion on Emerging Drugs, 2006
- Trojan Horse Meets Magic Bullet to Spawn a Novel, Highly Effective Drug Delivery ModelChemotherapy, 2006
- Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin BJournal of Lipid Research, 2006
- Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteinsEuropean Journal of Medicinal Chemistry, 2000
- Getting a Handle on “Good” Cholesterol with the High-Density Lipoprotein ReceptorNew England Journal of Medicine, 1999
- Synthesis of the Dioleoyl Derivative of Iododeoxyuridine and Its Incorporation into Reconstituted High Density Lipoprotein ParticlesBiochemistry, 1994
- Low density lipoprotein‐receptor activity is lost in vivo in malignantly transformed renal tissueFEBS Letters, 1986
- Interaction of estradiol and high density lipoproteins on proliferation of the human breast cancer cell line MCF-7 adapted to grow in serum free conditionsBiochemical and Biophysical Research Communications, 1985
- Inefficient internalization of receptor-bound low density lipoprotein in human carcinoma A-431 cells.Journal of Cell Biology, 1981